Endogenex Announces Full Enrollment of the ReCET Clinical Study

Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), announced that the ReCET Clinical Study has reached full enrollment. A total of 350 patients have been enrolled across approximately 40 clinical sites in the United States and Australia.